Snake Venom and Ecology 2022
DOI: 10.5772/intechopen.101421
|View full text |Cite
|
Sign up to set email alerts
|

Snake Venom and Therapeutic Potential

Abstract: Many active secretions produced by animals have been employed in the development of new drugs to treat diseases such as hypertension and cancer. Snake venom toxins contributed significantly to the treatment of many medical conditions. Snake venoms are the secretion of venomous snakes, which are synthesized and stored in specific venom glands. Many toxins from snake venom are investigated and formulated into drugs for the treatment of conditions such as cancer, hypertension, and thrombosis. Most of the venoms a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 96 publications
0
1
0
Order By: Relevance
“…), a complex mixture composed of different proteins, peptides, and compounds that have not yet been well identified [65,66]. Some compounds, or the in toto mixture, may have vasoconstrictor [67,68] or anti-inflammatory [69][70][71] effects, which could help to reduce the effect of the migraine. [72] reported a study on novel CGRP receptor antagonists for migraine therapy that involved improving the antagonist potency of the known peptide ( 34 Pro, 35 Phe)CGRP 27-37 through the structural modification of truncated C-terminal CGRP peptides.…”
Section: Innovative Medicinesmentioning
confidence: 99%
“…), a complex mixture composed of different proteins, peptides, and compounds that have not yet been well identified [65,66]. Some compounds, or the in toto mixture, may have vasoconstrictor [67,68] or anti-inflammatory [69][70][71] effects, which could help to reduce the effect of the migraine. [72] reported a study on novel CGRP receptor antagonists for migraine therapy that involved improving the antagonist potency of the known peptide ( 34 Pro, 35 Phe)CGRP 27-37 through the structural modification of truncated C-terminal CGRP peptides.…”
Section: Innovative Medicinesmentioning
confidence: 99%